MX2014004994A - Cisteamina en el tratamiento de enfermedad fibrotica. - Google Patents

Cisteamina en el tratamiento de enfermedad fibrotica.

Info

Publication number
MX2014004994A
MX2014004994A MX2014004994A MX2014004994A MX2014004994A MX 2014004994 A MX2014004994 A MX 2014004994A MX 2014004994 A MX2014004994 A MX 2014004994A MX 2014004994 A MX2014004994 A MX 2014004994A MX 2014004994 A MX2014004994 A MX 2014004994A
Authority
MX
Mexico
Prior art keywords
cysteamine
treatment
fibrotic disease
expression
extracellular matrix
Prior art date
Application number
MX2014004994A
Other languages
English (en)
Spanish (es)
Inventor
Daryl M Okamura
Allison A Eddy
Original Assignee
Seattle Children S Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Children S Res Inst filed Critical Seattle Children S Res Inst
Publication of MX2014004994A publication Critical patent/MX2014004994A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2014004994A 2011-10-26 2011-10-26 Cisteamina en el tratamiento de enfermedad fibrotica. MX2014004994A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/057935 WO2013062544A1 (en) 2011-10-26 2011-10-26 Cysteamine in the treatment of fibrotic disease

Publications (1)

Publication Number Publication Date
MX2014004994A true MX2014004994A (es) 2014-08-27

Family

ID=48168215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004994A MX2014004994A (es) 2011-10-26 2011-10-26 Cisteamina en el tratamiento de enfermedad fibrotica.

Country Status (7)

Country Link
US (2) US9468612B2 (https=)
AU (1) AU2011379972B2 (https=)
BR (1) BR112014009789A2 (https=)
CA (1) CA2853484C (https=)
IN (1) IN2014DN03049A (https=)
MX (1) MX2014004994A (https=)
WO (1) WO2013062544A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017004485A1 (en) * 2015-07-02 2017-01-05 Raptor Pharmaceuticals Inc. Ado-resistant cysteamine analogs and uses thereof
JP7418958B2 (ja) 2016-03-17 2024-01-22 チオジェネシス セラピューティクス， インコーポレイテッド システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
US10155948B2 (en) * 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
CA3052796A1 (en) * 2017-02-07 2018-08-16 Children's Hospital Medical Center Treatment of asthma with cysteamine
JP7208982B2 (ja) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド システアミン感受性障害の治療方法
US10828372B2 (en) 2017-11-10 2020-11-10 Wisconsin Alumni Research Foundation Compositions and methods for the inhibition of fibrosis
EP3866775B1 (en) 2018-10-17 2025-03-19 Novabiotics Limited Cysteamine for use in the treatment of lung diseases
WO2020210218A1 (en) * 2019-04-12 2020-10-15 The Regents Of The University Of California Methods for treating inherited eye defects
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549051B1 (fr) 1983-06-22 1986-05-16 Centre Nat Rech Scient Nouveaux agents radioprotecteurs ayant une structure amino-thioalkyle et procede pour leur preparation
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
AU633011B2 (en) 1988-06-28 1993-01-21 La Jolla Cancer Research Foundation Suppression of cell proliferation by decorin
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
WO1991004748A1 (en) 1989-09-29 1991-04-18 La Jolla Cancer Research Foundation INHIBITING TRANSFORMING GROWTH FACTOR β TO PREVENT ACCUMULATION OF EXTRACELLULAR MATRIX
ES2083469T3 (es) 1989-11-22 1996-04-16 Genentech Inc Peptido asociado a una latencia y utilizaciones del mismo.
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5554655A (en) 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
JP4124815B2 (ja) 1991-10-31 2008-07-23 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ ＴＧＦ−β型受容体ｃＤＮＡおよびその用途
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
ES2188585T3 (es) 1991-11-14 2003-07-01 Jolla Cancer Res Found Inhibidores de factores reguladores celulares y procedimientos para evitar o reducir la formacion de cicatrices.
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
CA2146973C (en) 1992-10-29 2008-09-02 Patricia R. Segarini Uses of tgf-.beta. receptor fragment as a therapeutic agent
AU5541094A (en) 1992-10-30 1994-05-24 Consejo Superior De Investigaciones Cientificas Compositions and methods for modifying the regulatory activity of tgf-beta
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
ATE235549T1 (de) 1993-04-30 2003-04-15 Biognostik Ges Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2
EP0737071A1 (en) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU8016894A (en) 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity
WO1995030900A1 (en) 1994-05-04 1995-11-16 Mount Sinai Hospital Corporation MODULATORS OF CYTOKINES OF THE TGF-β SUPERFAMILY AND METHODS FOR ASSAYING FOR SAME
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
EP0921809A4 (en) 1996-04-30 2001-10-24 Genzyme Corp USE OF PROLACTIN AS A TGF-BETA ANTAGONIST
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
DE69734894T2 (de) 1996-10-25 2006-07-20 Ethicon, Inc. Testverfahren für antifibrotischen wirkstoff
JP2001515360A (ja) 1997-04-18 2001-09-18 バイオジェン，インコーポレイテッド ▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
GB0102672D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
WO2002062787A1 (en) 2001-02-02 2002-08-15 Glaxo Group Limited Pyrazoles as tgf inhibitors
GB0102673D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
GB0102665D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
JP2004521915A (ja) 2001-02-02 2004-07-22 グラクソ　グループ　リミテッド Ｔｇｆ過剰発現に対するピラゾール誘導体
GB0102668D0 (en) 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1397364B1 (en) 2001-05-24 2007-07-25 Eli Lilly And Company Novel pyrrole derivatives as pharmaceutical agents
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AU2003224335A1 (en) 2002-05-15 2003-12-02 Smithkline Beecham Corporation Benzoxazine and benzoxazinone substituted triazoles
EP1511738A4 (en) 2002-05-17 2007-05-09 Scios Inc TREATMENT OF FIBROPROLIFERATIVE DISEASES USING TGF BETA INHIBITORS
AU2003256783A1 (en) 2002-07-25 2004-02-16 Scios, Inc. METHODS FOR IMPROVEMENT OF LUNG FUNCTION USING TGF-Beta INHIBITORS
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
JP2006503043A (ja) 2002-09-10 2006-01-26 サイオス インク． ＴＧＦβ阻害剤
US7365066B2 (en) 2002-09-17 2008-04-29 Eli Lilly And Company Pyrazolopyridine derivatives as pharmaceutical agents
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
US20040138188A1 (en) 2002-11-22 2004-07-15 Higgins Linda S. Use of TGF-beta inhibitors to counteract pathologic changes in the level or function of steroid/thyroid receptors
WO2004048930A2 (en) 2002-11-22 2004-06-10 Scios, Inc. METHOD FOR COUNTERACTING A PATHOLOGIC CHANGE IN THE ß-ADRENERGIC PATHWAY
AU2003291642A1 (en) 2002-11-22 2004-06-18 Eli Lilly And Company Pyrazoloazepine compounds as pharmaceutical agents
UA80571C2 (en) 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
AU2003290734A1 (en) 2002-11-27 2004-06-23 Eli Lilly And Company Novel compounds as pharmaceutical agents
CA2513086A1 (en) 2002-12-19 2004-07-08 Scios Inc. Treatment of obesity and associated conditions with tgf-.beta. inhibitors
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
JP2006521398A (ja) 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
CN1921864A (zh) 2003-12-24 2007-02-28 西奥斯公司 使用TGF－β抑制剂治疗神经胶质瘤
US7368445B2 (en) 2004-03-01 2008-05-06 Eli Lilly And Company Fused pyrazole derivatives as TGF-β signal transduction inhibitors for the treatment of fibrosis and neoplasms
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
DE102004019253A1 (de) 2004-04-16 2005-11-10 Codewrights Gmbh Verfahren zum Fernbedienen eines Feldgerätes der Prozessautomatisierungstechnik
CA2578630A1 (en) 2004-08-31 2006-03-09 Wen-Cherng Lee Pyrimidinylimidazoles as tgf-beta inhibitors
US20080171755A1 (en) 2004-08-31 2008-07-17 Wen-Cherng Lee Pyrimidinylpyrazoles as Tgf-Beta Inhibitors
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
EP3659588A1 (en) 2006-01-27 2020-06-03 The Regents of The University of California Enterically coated cysteamine and salts thereof
CA2708004C (en) 2006-12-04 2015-12-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
EP2636404B1 (en) * 2007-11-30 2019-03-20 The Regents of The University of California Methods of Treating Non-Alcoholic Steatohepatitis (Nash) Using Cysteamine Products

Also Published As

Publication number Publication date
IN2014DN03049A (https=) 2015-05-15
CA2853484A1 (en) 2013-05-02
US9925154B2 (en) 2018-03-27
AU2011379972B2 (en) 2016-05-12
CA2853484C (en) 2018-08-21
WO2013062544A1 (en) 2013-05-02
US20140275279A1 (en) 2014-09-18
US20170165207A1 (en) 2017-06-15
US9468612B2 (en) 2016-10-18
AU2011379972A1 (en) 2014-05-15
BR112014009789A2 (pt) 2017-04-25

Similar Documents

Publication Publication Date Title
MX2014004994A (es) Cisteamina en el tratamiento de enfermedad fibrotica.
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2013040078A3 (en) Engineered tissues for in vitro research uses, arrays thereof, and methods of making the same
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
MX353955B (es) Hebras de acido hialuronico reticulado y metodos de uso de las mismas.
CL2013002601A1 (es) Uso de 1-desoxigalactonojirimicina y una terapia de reemplazo de enzimas con alfa-gal a para tratar la enfermedad de fabry.
DOP2011000054A (es) Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar un paciente de acuerdo con la repuesta predicha
EP3888714B8 (en) Collagenous tissue pocket for an implantable medical device, and manufacturing method therefor
MX357749B (es) Tratamiento contra el dolor utilizando células madre placentarias.
WO2012038068A3 (en) Means and methods for the prediction of treatment response of a cancer patient
PH12013500876A1 (en) Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
WO2010007165A3 (en) Treatment of inflammatory diseases with mammal beta defensins
WO2010083495A3 (en) Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrin
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
BRPI1008517A2 (pt) direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
BR112013000433A2 (pt) diagnóstico e tratamento de câncer de mama
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
MX2013008530A (es) Peptidos a base de lactoferrina humana que tienen actividad antiinflamatoria.
EP2537513A3 (en) Use of anogeissus extract for fibrillin production in skin
WO2012048170A3 (en) Humanized animals via tissue engineering and uses therefor
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
SG11201804755VA (en) Method for manufacturing tissue/organ by using blood cells
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
MX2010006443A (es) TRATAMIENTO DE CARDIOPATIAS USANDO ß-BLOQUEANTES.